2020

• The founding team identifies a critical need in the healthcare sector: optimizing PRP treatments through data.
• First-hand experience highlights the need for better control and analysis of clinical data also by the circumstances and challenges during the COVID-19 pandemic.
• Initial idea for a data-driven platform in healthcare is born.
• The company is founded & PRP Data development begins focusing on transforming clinical management of PRP.
  

2021

• Launched the first version of our Minimum Viable Product (MVP), marking a key technical milestone.
• Faced our first major challenge lack of control in the development process — a turning point in the project — Responded by strengthening the team with new strategic partners, our CTO, to drive technological excellence.
• Presented our MVP to key opinion leaders in the healthcare sector, gaining valuable feedback and credibility.
• Secured our first collaboration agreements, unlocking additional funding and validating the potential of PRP Data.

2022

• Official market launch of PRP Data, with an improved version tailored to real clinical needs.
• Start of an active co-creation process with healthcare professionals to refine and evolve the platform.
• Established strategic alliances with scientific societies and research groups.
• Joined a pioneering multicenter observational study on PRP in osteoarthritis, promoted by SETRADE.
• Selected to the program ICEX NEXT to design our expansion strategy.
• First marketing strategies are defined, marking the beginning of our go-to-market roadmap.

2023

• Secured ENISA funding, enabling the formation of a highly skilled, multidisciplinary team.
• Tackled new technical, operational, and strategic challenges to scale the platform.
• Joined BIOIB (Biotechnology and Biomedical Cluster of the Balearic Islands), strengthening our innovation ecosystem.
• Began development of algorithms for product accuracy, treatment prediction, and personalized prescribing.
• Expanded into new medical specialties and treatments, broadening the platform’s clinical impact & officially launched BioSmartData as a comprehensive, AI-powered platform to support real-world clinical decision-making.
• Marked the beginning of a new phase of growth and national positioning in digital health.

2024

• Closed a new Smart Money funding round of 645.000 €, bringing in 14 Business Angels to boost professionalization and growth.
• Awarded a major FEDER-funded project (2.8M€ over 3 years), focused on standardizing chronic pain treatment across six specialties.
• Finalists at the NTT Data Foundation eAwards, showcasing our project in Bilbao before a panel of leading experts.
• Selected as one of the Top 101 companies in Spain Up Nation, promoted by ENISA.
• Honored with the Start-Up of the Year Award by Banco Sabadell, reinforcing our leadership in digital health innovation.
• Reached the TOP 10 semi-finals of the Web Summit PITCH, standing out among 3,000 companies and presenting BioSmartData on a global stage & gained exposure to over 20,000 international attendees, marking a milestone in our international positioning.

2025

• Execution of the chronic pain standardization project, collaborating with 6 specialties and multiple healthcare institutions.
• Begin the full-scale commercialization of BioSmartData in Spain and expand into strategic international markets.
• Close collaboration agreements with multinational companies, reinforcing our role as a technological partner in real-world evidence generation.
• Obtain official certification under the National Security Framework (ENS) and ISO 27001, ensuring the highest standards in information security and data protection.
  
• Deploy BioSmartData in new clinical specialties, including gynecology, broadening our clinical reach.
  
• Reinforced our team with new talent in development, data science, and commercial.
• Set the stage for our next investment round, focused on technological scale-up and global positioning.